Orexigen® Pipeline
Orexigen is developing compounds, each with specific characteristics to combat obesity. Orexigen continues to develop other product candidates addressing other central nervous system disorders.
None of the Orexigen product candidates have been approved for sale.
Contrave®; and Empatic are still being evaluated in clinical trials.
Clinical trials for Contrave are not currently enrolling new patients. Please see www.clinicaltrials.gov for more information.
Clinical trials for Empatic are not currently enrolling new patients.